LgR5 Expression and Its Role in Esophageal Adenocarcinomas
Author Information
Author(s): Burkhard H. A. von Rahden, Stefan Kircher, Maria Lazariotou, Christoph Reiber, Luisa Stuermer, Christoph Otto, Christoph T. Germer, Martin Grimm
Primary Institution: University Hospital Wuerzburg
Hypothesis
Does LgR5 expression help define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?
Conclusion
LgR5 is expressed in esophageal adenocarcinomas and is associated with poorer survival outcomes.
Supporting Evidence
- LgR5 was expressed in 85% of EAC with Barrett's Esophagus.
- LgR5 expression was significantly higher in Barrett's Esophagus compared to EAC.
- High LgR5 expression was associated with poorer survival outcomes.
Takeaway
This study looked at a marker called LgR5 in stomach cancer and found that it might help understand where the cancer comes from and how it affects survival.
Methodology
The study analyzed LgR5 expression in 70 esophageal cancer specimens using immunohistochemistry and RT-PCR.
Potential Biases
Potential bias due to the selection of archival tissue samples and the exclusion of patients who received preoperative therapies.
Limitations
The study is limited by its retrospective design and the small sample size of certain subgroups.
Participant Demographics
The study included 70 patients, with 41 having Barrett's Esophagus and 19 without, predominantly male.
Statistical Information
P-Value
0.0159
Confidence Interval
95% CI 24.761 - 39.954%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website